HC Wainwright Issues Positive Forecast for SRTS Earnings

Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) - Equities research analysts at HC Wainwright boosted their Q4 2025 earnings per share (EPS) estimates for shares of Sensus Healthcare in a note issued to investors on Friday, May 16th. HC Wainwright analyst Y. Chen now expects that the company will earn $0.20 per share for the quarter, up from their previous forecast of $0.19. HC Wainwright has a "Buy" rating and a $12.00 price objective on the stock. The consensus estimate for Sensus Healthcare's current full-year earnings is $0.32 per share. HC Wainwright also issued estimates for Sensus Healthcare's Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.03 EPS, Q3 2026 earnings at $0.02 EPS and Q4 2026 earnings at $0.20 EPS.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.20). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. The firm had revenue of $8.34 million during the quarter, compared to analyst estimates of $7.23 million.

A number of other brokerages have also recently issued reports on SRTS. Wall Street Zen cut Sensus Healthcare from a "hold" rating to a "sell" rating in a report on Thursday. Lake Street Capital lowered their target price on Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. Finally, Maxim Group lowered their target price on Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $11.67.

Sensus Healthcare Price Performance

Shares of SRTS traded up $0.01 during mid-day trading on Monday, reaching $4.69. The company had a trading volume of 41,205 shares, compared to its average volume of 208,082. Sensus Healthcare has a twelve month low of $4.01 and a twelve month high of $9.33. The company's 50-day moving average is $4.61 and its 200-day moving average is $6.06. The company has a market capitalization of $77.13 million, a P/E ratio of 11.73 and a beta of 1.30.

Hedge Funds Weigh In On Sensus Healthcare

A number of institutional investors have recently bought and sold shares of the business. Acadian Asset Management LLC increased its position in Sensus Healthcare by 35.3% during the first quarter. Acadian Asset Management LLC now owns 470,713 shares of the company's stock worth $2,225,000 after buying an additional 122,746 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Sensus Healthcare by 5.3% during the fourth quarter. Renaissance Technologies LLC now owns 430,934 shares of the company's stock worth $2,982,000 after acquiring an additional 21,600 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Sensus Healthcare by 30.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 378,568 shares of the company's stock worth $2,620,000 after acquiring an additional 88,953 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Sensus Healthcare by 81.2% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 150,150 shares of the company's stock worth $1,039,000 after acquiring an additional 67,269 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Sensus Healthcare by 3.9% during the first quarter. Bank of New York Mellon Corp now owns 141,971 shares of the company's stock worth $672,000 after acquiring an additional 5,289 shares during the period. Institutional investors and hedge funds own 25.30% of the company's stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.